2024
Artificial intelligence applied to electrocardiographic images for the risk stratification of cancer therapeutics-related cardiac dysfunction
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial intelligence applied to electrocardiographic images for the risk stratification of cancer therapeutics-related cardiac dysfunction. European Heart Journal 2024, 45: ehae666.3190. DOI: 10.1093/eurheartj/ehae666.3190.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionImmune checkpoint inhibitorsGlobal longitudinal strainLeft ventricular systolic dysfunctionNon-Hodgkin's lymphomaCardiac dysfunctionAI-ECGNegative control analysesAssociated with higher incidenceVentricular systolic dysfunctionCohort of patientsRisk stratification strategiesCheckpoint inhibitorsTrastuzumab exposureSystolic dysfunctionRisk stratificationBreast cancerRisk biomarkersSecondary outcomesLongitudinal strainStratification strategiesTrastuzumabPatientsHigher incidenceAnthracyclinesArtificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images. Circulation Cardiovascular Quality And Outcomes 2024 PMID: 39221857, DOI: 10.1161/circoutcomes.124.011504.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular systolic dysfunctionCardiac dysfunctionBreast cancerNon-Hodgkin lymphoma therapyNon-Hodgkin's lymphomaVentricular systolic dysfunctionAssociated with worse global longitudinal strainRisk stratification strategiesHigh-risk groupMonths post-treatmentPost hoc analysisElectrocardiographic (ECGTrastuzumab exposureLymphoma therapySystolic dysfunctionAI-ECGBefore treatmentRisk biomarkersLongitudinal strainLow riskStratification strategiesHigher incidencePositive screen
2020
Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis
Norouzi S, Javinani A, Aminorroaya A, Masoumi M. Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis. BMC Cardiovascular Disorders 2020, 20: 390. PMID: 32847506, PMCID: PMC7448352, DOI: 10.1186/s12872-020-01676-x.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionCardiac systolic dysfunctionCardiovascular diseaseSystolic dysfunctionRheumatoid arthritisReduced left ventricular ejection fractionPredictors of left ventricular ejection fractionAnti-modified citrullinated vimentinEchocardiographic parameters of systolicDisease Activity Score-28Anti-MCV levelsParameters of systolicAssociation of autoantibodiesVentricular ejection fractionConcomitant cardiovascular diseaseExclusion of patientsSusceptibility to cardiovascular diseaseReceiver operating characteristic curveDuration of diseaseCardiovascular disease risk factorsAnti-citrullinated proteinFramingham risk scoreCross-sectional studyTransthoracic echocardiographyDiastolic dysfunction